Medicine Recommendations

Immunisation against herpes zoster

Use in high-risk patients for prevention of recurrence or upon recurrence of Crohn's Disease following surgery.

First, second and third-line treatment of moderately to severely active Crohn's disease after prior therapy (NICE TA352)

NICE TA 352 - Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy

First, second and third-line treatment of moderately to severely active ulcerative colitis (NICE TA342)

NICE TA 342 - Vedolizumab for treating moderately to severely active ulcerative colitis

Prevention of recurrence of ulcerative colitis following surgery.

Depressive illness, generalised anxiety disorder (XL formulation only)

Following a gastric bypass

Following bariatric surgery performed privately. 

Following a sleeve gastrectomy

Asymptomatic patients that are at high or normal risk of vitamin D deficiency

Prophylaxis or maintenance, following treatment of deficiency and insufficiency for symptomatic individuals that are at high or normal risk of vitamin D deficiency

For the correction of deficiency and insufficiency in high-risk, symptomatic patients as a short-course treatment. 

For additional prescribing information see Vitamin D Prescriber Resources in our Clinical Resources section

Nicotine Replacement Therapy

Please note: eVoke and Voke are different products. For eVoke see 'Electronic-cigarettes (e-cigarettes)'

Major depressive episodes

NICE TA367 - Vortioxetine for treating major depressive episodes

Prevention of stroke and systemic embolism in non-valvular atrial fibrillation

 Treatment of venous thromboembolism

Influenza treatment & prophylaxis

NICE TA158 - Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza

NICE TA168 - Amantadine, oseltamivir and zanamivir for the treatment of influenza

Glucocorticoid-induced osteoporosis

NICE TA 464 - Bisphosphonates for treating osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures

Osteoporosis (NICE TA464)

NICE TA 464 - Bisphosphonates for treating osteoporosis

MHRA Drug Safety Update - Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update - Bisphosphonates: atypical femoral fractures